| FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations LN Mathieu, E Larkins, O Akinboro, P Roy, AK Amatya, MH Fiero, ... Clinical Cancer Research 28 (2), 249-254, 2022 | 74 | 2022 |
| Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed/refractory multiple myeloma: a phase 1/2 first-in-human study N Bumma, J Richter, J Brayer, JA Zonder, M Dhodapkar, MR Shah, ... Blood 140 (Supplement 1), 10140-10141, 2022 | 25 | 2022 |
| Response of single leukemic cells to peptidase inhibitor therapy across time and dose using a microfluidic device ML Kovarik, AJ Dickinson, P Roy, RA Poonnen, JP Fine, NL Allbritton Integrative biology 6 (2), 164-174, 2014 | 14 | 2014 |
| Exploration of baseline patient-reported side effect bother from cancer therapy JK Roydhouse, BL King-Kallimanis, P Roy, C Weinstock, D Krol, ... Clinical Trials 17 (3), 332-337, 2020 | 10 | 2020 |
| FDA analysis of ECOG performance status and safety outcomes. H Singh, Y Gong, P Roy, B King-Kallimanis, V Bhatnagar, R Pazdur, ... Journal of Clinical Oncology 38 (15_suppl), 12024-12024, 2020 | 7 | 2020 |
| Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL) A Majumdar, R Rothwell, G Reaman, C Ahlberg, P Roy Journal of Biopharmaceutical Statistics 33 (6), 737-751, 2023 | 2 | 2023 |
| Statistical Considerations in Pediatric Cancer Trials: Report of American Statistical Association Biopharmaceutical Section Open Forum Discussions R Sridhara, O Marchenko, Q Jiang, E Barksdale, TA Alonzo, A Amatya, ... Statistics in Biopharmaceutical Research 15 (4), 845-851, 2023 | 2 | 2023 |
| FDA approval summary: Nivolumab for the adjuvant treatment of adults with completely resected esophageal/gastroesophageal junction cancer and residual pathologic disease MN Horiba, SJ Casak, PS Mishra-Kalyani, P Roy, JA Beaver, R Pazdur, ... Clinical Cancer Research 28 (24), 5244-5248, 2022 | 2 | 2022 |
| Trial in progress: REGN5458, a BCMAxCD3 bispecific antibody, in a phase Ib multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma P Rodríguez Otero, NS Joseph, SK Kumar, HC Lee, X Leleu, S Manier, ... Blood 140 (Supplement 1), 4444-4446, 2022 | 2 | 2022 |
| Trial in progress: a phase II window of opportunity study of the BCMAxCD3 bispecific antibody REGN5458 in previously untreated patients with symptomatic multiple myeloma CJ Ferreri, SE Quatela, S Aina, P Roy, A Boyapati, K Rodriguez Lorenc, ... Blood 140 (Supplement 1), 10129-10130, 2022 | 2 | 2022 |
| Standardization and validation of a novel and simple method to assess lumbar dural sac size MLA Daniels, JR Lowe, P Roy, MV Patrone, JM Conyers, JP Fine, ... Clinical radiology 70 (2), 146-152, 2015 | 1 | 2015 |
| P-046 Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple … P Rodriguez-Otero, N Joseph, S Kumar, X Leleu, S Manier, ... Clinical Lymphoma Myeloma and Leukemia 23, S60, 2023 | | 2023 |
| PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE … CJ Ferreri, S Quatela, O Aina, P Roy, A Boyapati, KR Lorenc, G Kroog, ... HemaSphere 7 (Suppl), 2023 | | 2023 |
| Efficiency of naive estimators for accelerated failure time models under length‐biased sampling P Roy, JP Fine, MR Kosorok Scandinavian Journal of Statistics 2021, 1– 17, 2021 | | 2021 |
| Multidisciplinary Review of Avapritinib et.al. Christy Osgood, Ashley Ward, Pourab Roy, Pallavi Mishra-Kalyani ... https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020 …, 2020 | | 2020 |
| Predicting Future OS Behavior using Bayesian Posterior Predictive Distributions P Roy, E Bloomquist Joint Statistical Meetings, 2020 | | 2020 |
| Efficient estimation of accelerated lifetime models under length-biased sampling P Roy, JP Fine, MR Kosorok arXiv preprint arXiv:1904.02624, 2019 | | 2019 |
| Non-parametric and Semi-parametric Estimation in Forward and Backward Recurrence Time Data P Roy University of North Carolina at Chapel Hill Graduate School, 2015 | | 2015 |
Bellinda King-KallimanisLUNGevity FoundationVerified email at lungevity.org
